Apreo Health | $130,000,000 | (Aug 12, 2025)
Orbital Operations | $8,800,000 | (Aug 12, 2025)
Perle | $9,000,000 | (Aug 12, 2025)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
Edumentors | $2,000,000 | (Aug 12, 2025)
August Health | $29,000,000 | (Aug 12, 2025)
BinSentry | $50,000,000 | (Aug 12, 2025)
Lava | $5,800,000 | (Aug 12, 2025)
Certivity | $15,458,285 | (Aug 12, 2025)
Swirltex Inc. | $1,200,000 | (Aug 12, 2025)
Tahoe Therapeutics | $30,000,000 | (Aug 12, 2025)
Neuralzome Cybernetics | $2,400,000 | (Aug 12, 2025)
Translucent(US) | $7,000,000 | (Aug 12, 2025)